Baseline demographics by group, UC and HM
| UC (n=92) | HM (n=90) | |
|---|---|---|
| Age, years, mean (SD) | 67.3 (7.6) | 68.2 (7.9) |
| Gender, male | 47 (51) | 49 (54) |
| BMI, mean (SD) | 26.7 (4.8) | 26.3 (4.9) |
| Living alone | 39 (42) | 36 (40) |
| Education level | ||
| ≤Year 10 | 69 (75) | 60 (68) |
| Year 11–12 | 7 (8) | 12 (13) |
| Postschool qualification | 16 (17) | 18 (20) |
| Currently employed | 17 (19) | 18 (20) |
| Smoking history pack-years mean (SD)* | 43.4 (21.4) | 53.9 (26.3) |
| Current smoker | 33 (36) | 43 (48) |
| FEV1 % predicted mean (SD) | 56.4 (13.2) | 54.0 (13.4) |
| MRC Dyspnoea Score (1–5) | 2.5 (0.9) | 2.8 (1.2) |
| Other comorbidities, mean (SD) | 1.7 (1.4) | 1.6 (1.3) |
| Prior pulmonary rehabilitation or CDSM education | 17 (19) | 19 (21) |
| ≥1 Antibiotic course within 12 months | 44 (48) | 47 (53) |
| ≥1 Oral corticosteroid course within 12 months | 18 (20) | 18 (20) |
| Admission for COPD in past 12 months reported | 0 (0) | 5 (6) |
| Influenza vaccination in past 12 months | 76 (82) | 72 (80) |
| Pneumococcal vaccination in past 5 years | 61 (66) | 60 (67) |
| Medication at baseline (based on UC n=83 and HM n=63) | ||
| Inhaled short-acting bronchodilator | 47 (57) | 27 (44) |
| Inhaled long-acting bronchodilator | 69 (83) | 42 (69) |
| Inhaled corticosteroids | 48 (58) | 29 (48) |
| Oral steroids | 5 (6) | 2 (3) |
Values are n (%) unless stated otherwise.
*p<0.05.
BMI, body mass index; CDSM, chronic disease self-management; HM, health mentoring; MRC, Medical Research Council; UC, usual care.